LNTH
$80.45
Lantheus Holdings, Inc.
Intraday
Recent News
Why Lantheus (LNTH) Is Up 5.4% After Dual FDA Wins In Radiopharmaceutical Oncology Expansion
Lantheus Holdings recently received FDA approval for PYLARIFY TruVu, an enhanced formulation of its PSMA PET imaging agent designed to improve manufacturing efficiency and geographic reach for prostate cancer diagnostics. The company also secured tentative FDA approval for a radioequivalent version of LUTATHERA for GEP‑NETs, further extending its presence in radiopharmaceutical oncology and potentially broadening its future revenue base. We’ll now examine how the new high-yield PYLARIFY...
3 Reasons to Sell LNTH and 1 Stock to Buy Instead
What a fantastic six months it’s been for Lantheus. Shares of the company have skyrocketed 57%, hitting $83.14. This run-up might have investors contemplating their next move.
Q4 Earnings Highlights: Lantheus (NASDAQ:LNTH) Vs The Rest Of The Medical Devices & Supplies - Imaging, Diagnostics Stocks
Let’s dig into the relative performance of Lantheus (NASDAQ:LNTH) and its peers as we unravel the now-completed Q4 medical devices & supplies - imaging, diagnostics earnings season.
Why Lantheus Holdings Stock Popped by Almost 12% Last Month
Investors were clearly impressed by the medical device specialist's fourth-quarter performance.
Assessing Lantheus Holdings (LNTH) Valuation After Recent Share Price Rebound And PYLARIFY Outlook
Lantheus Holdings (LNTH) is drawing investor attention after recent trading left the shares about 20% below some published fair value estimates, despite reported annual revenue of US$1.54b and net income of US$233.56m. See our latest analysis for Lantheus Holdings. The recent 30 day share price return of 11.94% and 90 day share price return of 26.79% suggest momentum has been rebuilding, even though the 1 year total shareholder return is still down 20.16% and the 3 year total shareholder...